Key Points | National Lipid Association Scientific Statement on Icosapent Ethyl

This scientific statement from the National Lipid Association recommends icosapent ethyl for cardiovascular risk reduction in select patients and is largely based on results of REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial). Evidence for this recommendation is newly available since finalization of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.

Read the Key Points